CLINICAL_TRIALS
trial_result
· 2022-12-06
Clinical Trial Update: Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia [Phase 3]
Summary
Phase 3 trial results for blinatumomab in younger patients with relapsed B-cell acute lymphoblastic leukemia have been posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent B Acute Lymphoblastic Leukemia | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2022-12-06